Effects of infliximab treatment in terms of cardiovascular risk and insulin resistance in ankylosing spondylitis patients

References

• Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation. 2005;112(21):3337–47.
   PubMed Web of Science ®Google Scholar
• Mathieu S, Joly H, Baron G, Tournadre A, Dubost JJ, Ristori JM, et al. Trend towards increased arterial stiffness or intima–media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology (Oxford). 2008;47(8):1203–1207.
   PubMed Web of Science ®Google Scholar
• American Heart Association. Heart Disease and Stroke Statistics — 2006 Update. Dallas, Texas: American Heart Association 2006. Available from: http//www.americanheart.org.
   Google Scholar
• Fowkes FG, Housley E, Riemersma RA, Macintyre CC, Cawood EH, Prescott RJ, Ruckley CV. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol. 1992;135(4):331–340.
   PubMed Web of Science ®Google Scholar
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95.
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340(2):15–26.
   Web of Science ®Google Scholar
• Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how ‘‘high-grade’’ systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003;108(24):2957–63.
   PubMed Web of Science ®Google Scholar
• Bernstein LE, Berry J, Kim S, Canavan B, Grinspoon SK. Effects of etanersept in patients with the metabolic syndrome. Arch Intern Med. 2006;166(8):902–8.
   PubMedGoogle Scholar
• Ferrari R. The role of TNF in cardiovascular disease. Pharmacol Res. 1999;40(2):97–105.
   PubMed Web of Science ®Google Scholar
• Lee HT, Chen WS, Chen MH, Tsai CY, Chou CT. The expression of proinflammatory cytokines and intracellular minerals in patients with ankylosing spondylitis. Formosan J Rheumatol. 2009;23:40–6.
   Google Scholar
• Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of Coronary Heart Disease Using Risk Factor Categories. Circulation. 1997;97(18):1837–47.
   Web of Science ®Google Scholar
• Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for anklosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361–8.
   PubMed Web of Science ®Google Scholar
• Garret S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Anklosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286–91.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.
   PubMed Web of Science ®Google Scholar
• Calin A, Garret S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, Jenkinson T. A new approach to defining functional ability in anklosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21(12):2281–5.
   PubMed Web of Science ®Google Scholar
• Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis. 2003;62(1):20–6.
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002; 106(25):3143–421.
   PubMed Web of Science ®Google Scholar
• McCarey D, Sturrock RD. Comparison of cardiovascular risk in ankylosing spondylitis and rheumatoid arthritis. Clin Exp Rheumatol. 2009;27(4):124–6.
   PubMed Web of Science ®Google Scholar
• Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003;108(24):2957–63.
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917): 868–74.
   PubMed Web of Science ®Google Scholar
• Carter AM. Inflammation, thrombosis and acute coronary syndromes. Diab Vasc Dis Res. 2005;2(3):113–21.
   PubMedGoogle Scholar
• Grignani G, Maiolo A. Cytokines and hemostasis. Haematologica. 2000;85(9):967–72.
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87–91.
   PubMed Web of Science ®Google Scholar
• Jacobsson LT, Turesson C, Gülfe A, Kapetanovic MC, Petersson IF, Saxne T, Geborek P. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol. 2005;32(7):1213–8.
   PubMed Web of Science ®Google Scholar
• Dixon WG, Watson KD, Lunt M, Hyrich KL, , British Society for Rheumatology Biologics Register Control Centre ConsortiumSilman AJ, Symmons DP, British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007;56(9):2905–12.
   PubMed Web of Science ®Google Scholar
• Kiortsis DN, Mavridis AK, Filippatos TD, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol. 2006;33(5):921–3.
   PubMed Web of Science ®Google Scholar
• Popa C, van Den Hoogen FH, Radstake TR, Netea MG, Eijsbouts AE, van Den Heijer M, et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis. 2007;66(11): 1503–7.
   PubMed Web of Science ®Google Scholar
• da Silva BS, Bonfá E, de Moraes JC, Saad CG, Ribeiro AC, Gonçalves CR, de Carvalho JF. Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis. Biologicals. 2010;38(5):567–9.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, de Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J, Llorca J. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006;24(1):83–6.
   PubMed Web of Science ®Google Scholar
• Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure?A meta-analysis. Ann Intern Med. 1994;121(4):289–300.
   PubMed Web of Science ®Google Scholar
• Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153(4):477–84.
   PubMedGoogle Scholar
• Weir MR. Renal effects of nonselective NSAIDs and coxibs. Cleve. Clin. J. Med. 2002;69(1):53–8.
   Google Scholar
• Sandoo A, Panoulas VF, Toms TE, Smith JP, Stavropoulos-Kalinoglou A, Metsios GS, et al. Anti-TNF α therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis. J Hum Hypertens. 2011; 28:1–4.
   Google Scholar
• Olivia F, Marshall T. Is Cardiovascular Risk being Effectively Monitored and Managed in Patients with in Patients with Inflammatory Polyarthritis? Reinvention: a Journal of Undergraduate Research 2010 [serial on the Internet]; 3(2). Available from: http://www2.warwick.ac.uk/fac/cross_fac/iatl/ejournal/issues/volume3issue2/
   Google Scholar
• Kannel WB. Elevated systolic blood pressure as a cardiovascular risk factor. Am J Cardiol. 2000;85(2):251–5.
   PubMed Web of Science ®Google Scholar
• Klarenbeek NB, van der Kooij SM, Huizinga TJ, Goekoop- Ruiterman YP, Hulsmans HM, van Krugten MV, et al. Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. Ann Rheum Dis. 2010 Jul;69(7):1342–5.
   PubMed Web of Science ®Google Scholar
• Filho AG, Kinote A, Pereira DJ, Rennó A, Dos Santos RC, Ferreira-Melo SE, et al. Infliximab prevents increased systolic blood pressure and upregulates the AKT/eNOS pathway in the aorta of spontaneously hypertensive rats. Eur J Pharmacol. 2013 Jan 30;700(1–3):201–9.
   PubMed Web of Science ®Google Scholar
• Scotece M, Conde J, Gómez R, López V, Pino J, González A, et al. Role of Adipokines in Atherosclerosis: Interferences with Cardiovascular Complications in Rheumatic Diseases. Mediators Inflamm. 2012;2012:125458. doi: 10.155/2012/12558.
   Web of Science ®Google Scholar
• Nagashima T, Okubo-Fornbacher H, Aoki Y, Kamata Y, Kimura H, Kamimura T et al. Increase in plasma levels of adiponectin after administration of anti-tumor necrosis factor agents in patients with rheumatoid arthritis. J Rheumatol 2008;35(5):936–8.
   PubMed Web of Science ®Google Scholar
• Derdemezis CS, Filippatos TD, Voulgari PV, Tselepis AD, Drosos AA, Kiortsis DN. Leptin and adiponectin levels in patients with ankylosing spondylitis. The effect of infliximab treatment. Clin Exp Rheumatol. 2010;28(6):880–3.
   PubMed Web of Science ®Google Scholar
• Miranda-Filloy JA, López-Mejias R, Genre F, Carnero-López B, Ochoa R, Diaz de Terán T, et al. Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy. Clin Exp Rheumatol. 2013;31(3):365–71.
   PubMed Web of Science ®Google Scholar